Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
ORGANIZATION
JPMA to Overhaul Guideline for Handling Drug Inquiries This Fall: Consultation Chair
The Japan Pharmaceutical Manufacturers Association’s (JPMA) Consumer Consultation Review Committee will this fall release a major revision of its guideline for handling drug inquiries at member companies, the first update since 2020. Committee chair Masahiro Wakasugi said the new edition…
To read the full story
Related Article
- JPMA Think Tank Chief Pledges to Back Policy Debates with Evidence
September 26, 2025
- JPMA Publishes TPP Overview to Bridge Academia and Industry: R&D Chair
September 22, 2025
- JPMA Sets Up Multilateral Advocacy Group to Bolster Global Voice: International Affairs Chair
September 19, 2025
- JPMA Launches Task Force on AI and Open Innovation Challenges: IP Chief
September 18, 2025
- JPMA to Broaden Base of Biopharma Talent through On-Site Training: Committee Chair
September 17, 2025
- JPMA to Compile Best Practices on Patient and Public Involvement
September 16, 2025
- JPMA Plans Joint Training with HCPs to Improve Promo Materials: Review Board Chair
September 11, 2025
- JPMA to Step Up Public Outreach, Build Understanding of Pharma, Says PR Head
September 10, 2025
- JPMA Quality Committee Launches Task Force on DX in Commercial Production
September 9, 2025
- JPMA Code & Compliance Chair Stresses Need to Embed Spirit of Revised COP
September 8, 2025
- JPMA ICH Project Chair Sees RWE as Potential Complement to Clinical Trials
September 5, 2025
- Rules for Measuring Industry-Wide Emissions in the Works: JPMA Environment Chief
September 4, 2025
- JPMA Regulatory Chief Seeks Balanced Approach on Japanese PI Waivers
September 3, 2025
- Clinical Trial Environment Must Match Global Standards, Says JPMA Evaluation Chief
September 2, 2025
- Information Provisioning on Solo Channels Is Duty of Both Makers and Wholesalers: JPMA Distribution Chief
September 1, 2025
- Indicators Needed to Frame Pharma as Growth Market in Japan, Says JPMA Policy Chief
August 29, 2025
ORGANIZATION
- BCG’s Takeda Questions Conditional Pricing for Regenerative Medicines
March 25, 2026
- Industry Groups Push Mindset Shift to Streamline Japan’s Clinical Trials
March 24, 2026
- FY2027 Off-Year Drug Price Revision Already Decided: Kenporen Director
March 24, 2026
- FPMAJ Calls for Drug Price Hike, End to Off-Year Revisions in FY2026 Plan
March 23, 2026
- JPMA Names Shionogi’s Go Takahashi as Managing Director
March 23, 2026
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…